Larosa M, Ferretti S, Salsi P, Simonazzi M
Divisione di Urologia, Ospedale Maggiore, Parma.
Acta Biomed Ateneo Parmense. 1994;65(1-2):23-8.
Dynamic and static factors cause infravesical obstruction in men with BPH. The dynamic component is determined by alpha 1-adrenoceptor-mediated contractions of the prostate smooth muscle and bladder neck. Using alpha-receptor-blockers will relieve bladder outlet obstruction, improving urinary flow rates and obstructive and irritative symptoms as well as the physician's global assessment. This study was performed to evaluate the efficacy and safety of alpha 1 blockers (terazosin and alfuzosin) in ambulatory patients (n = 20) with BPH. After 24 weeks of therapy, the peak flow rate increased 54% from a baseline average of 8.5 ml/s to 13.1 ml/s (p < 0.01). The mean flow rate increased 49%, from a baseline of 4.61 ml/s to 6.9 ml/s (p < 0.01); residual volume decreased 74% from 48.3 ml to 12.5 ml (p < 0.001). Mean systolic blood pressure decreased significantly (p < 0.05) from baseline, but this change wasn't clinically important. The clinical experience with alpha-blockers in BPH indicates that these drugs increase urinary flow rates, decrease obstructive and irritative symptoms, without serious side effects.
动态和静态因素导致良性前列腺增生（BPH）男性患者膀胱颈以下梗阻。动态因素由α1肾上腺素能受体介导的前列腺平滑肌和膀胱颈收缩决定。使用α受体阻滞剂可缓解膀胱出口梗阻，改善尿流率、梗阻性和刺激性症状以及医生的整体评估。本研究旨在评估α1阻滞剂（特拉唑嗪和阿夫唑嗪）对门诊BPH患者（n = 20）的疗效和安全性。治疗24周后，最大尿流率从基线平均8.5 ml/s增加54%至13.1 ml/s（p < 0.01）。平均尿流率增加49%，从基线4.61 ml/s增至6.9 ml/s（p < 0.01）；残余尿量从48.3 ml减少74%至12.5 ml（p < 0.001）。平均收缩压较基线显著降低（p < 0.05），但这一变化在临床上并不重要。α阻滞剂治疗BPH的临床经验表明，这些药物可增加尿流率，减轻梗阻性和刺激性症状，且无严重副作用。
